These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 16284917)

  • 1. Some considerations on the design of population pharmacokinetic studies.
    Duffull S; Waterhouse T; Eccleston J
    J Pharmacokinet Pharmacodyn; 2005 Aug; 32(3-4):441-57. PubMed ID: 16284917
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An evaluation of population D-optimal designs via pharmacokinetic simulations.
    Hooker AC; Foracchia M; Dodds MG; Vicini P
    Ann Biomed Eng; 2003 Jan; 31(1):98-111. PubMed ID: 12572660
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics. A regulatory perspective.
    Sun H; Fadiran EO; Jones CD; Lesko L; Huang SM; Higgins K; Hu C; Machado S; Maldonado S; Williams R; Hossain M; Ette EI
    Clin Pharmacokinet; 1999 Jul; 37(1):41-58. PubMed ID: 10451782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simultaneous population optimal design for pharmacokinetic-pharmacodynamic experiments.
    Hooker A; Vicini P
    AAPS J; 2005 Nov; 7(4):E759-85. PubMed ID: 16594631
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A pharmacometric case study regarding the sensitivity of structural model parameter estimation to error in patient reported dosing times.
    Knights J; Rohatagi S
    J Pharmacokinet Pharmacodyn; 2015 Dec; 42(6):627-37. PubMed ID: 26209956
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Optimal population designs for PK models with serial sampling.
    Gagnon R; Leonov S
    J Biopharm Stat; 2005; 15(1):143-63. PubMed ID: 15702610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Optimal sampling schedule design for populations of patients.
    Tam VH; Preston SL; Drusano GL
    Antimicrob Agents Chemother; 2003 Sep; 47(9):2888-91. PubMed ID: 12936990
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimisation of sampling windows design for population pharmacokinetic experiments.
    Ogungbenro K; Aarons L
    J Pharmacokinet Pharmacodyn; 2008 Aug; 35(4):465-82. PubMed ID: 18780163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Optimization of individual and population designs using Splus.
    Retout S; Mentré F
    J Pharmacokinet Pharmacodyn; 2003 Dec; 30(6):417-43. PubMed ID: 15000423
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of the Size of Cohorts in Adaptive Design for Nonlinear Mixed Effects Models: An Evaluation by Simulation for a Pharmacokinetic and Pharmacodynamic Model for a Biomarker in Oncology.
    Lestini G; Dumont C; Mentré F
    Pharm Res; 2015 Oct; 32(10):3159-69. PubMed ID: 26123680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetically based estimation of patient compliance with oral anticancer chemotherapies: in silico evaluation.
    Hénin E; Tod M; Trillet-Lenoir V; Rioufol C; Tranchand B; Girard P
    Clin Pharmacokinet; 2009; 48(6):359-69. PubMed ID: 19650675
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of dosing impact on intra-individual variability in estimation of parameters for basic indirect response models.
    Krzyzanski W; Dmochowski J; Matsushima N; Jusko WJ
    J Pharmacokinet Pharmacodyn; 2006 Oct; 33(5):635-55. PubMed ID: 16941234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-compartmental estimation of pharmacokinetic parameters in serial sampling designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2009 Oct; 36(5):479-94. PubMed ID: 19847629
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics, optimised design and sample size determination for rifampicin, isoniazid, ethambutol and pyrazinamide in the mouse.
    Chen C; Ortega F; Alameda L; Ferrer S; Simonsson US
    Eur J Pharm Sci; 2016 Oct; 93():319-33. PubMed ID: 27473307
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.
    Hashimoto Y; Sheiner LB
    J Pharmacokinet Biopharm; 1991 Jun; 19(3):333-53. PubMed ID: 1875286
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretation of simulation studies for efficient estimation of population pharmacokinetic parameters.
    Ette EI; Kelman AW; Howie CA; Whiting B
    Ann Pharmacother; 1993 Sep; 27(9):1034-9. PubMed ID: 8117353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of underlying assumptions on evaluating the relative merits of concentration-controlled and dose-controlled trials.
    Lledó-García R; Hennig S; Karlsson MO
    Clin Pharmacol Ther; 2009 Jul; 86(1):70-6. PubMed ID: 19279565
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A general method to determine sampling windows for nonlinear mixed effects models with an application to population pharmacokinetic studies.
    Foo LK; McGree J; Duffull S
    Pharm Stat; 2012; 11(4):325-33. PubMed ID: 22411749
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Incorporating prior parameter uncertainty in the design of sampling schedules for pharmacokinetic parameter estimation experiments.
    D'Argenio DZ
    Math Biosci; 1990 Apr; 99(1):105-18. PubMed ID: 2134510
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetic design optimization in children and estimation of maturation parameters: example of cytochrome P450 3A4.
    Bouillon-Pichault M; Jullien V; Bazzoli C; Pons G; Tod M
    J Pharmacokinet Pharmacodyn; 2011 Feb; 38(1):25-40. PubMed ID: 21046208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.